| 货号 | 11022-100mg |
| 描述 | BIBF 1120 is a triple receptor tyrosine kinase inhibitor, blocking signaling through VEGFR (IC50 = 13-34 nM), PDGFR (IC50 = 59-65 nM), and FGFR (IC50 = 37-610 nM).1 As all of these receptors are involved in angiogenesis, BIBF 1120 has utility in diseases that require new vessel formation. For example, BIBF 1120 has potential applications in various forms of cancer and pulmonary fibrosis.2,3,4,5,6 |
| 别名 | Nintedanib;Vargatef™; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Hilberg, F.,Roth, G.J.,Krssak, M., et al. BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Research 68(12), 4774-4782 (2008). 2.Miyazaki, K.,Collins, D.J.,Walker-Samuel, S., et al. Quantitative mapping of hepatic perfusion index using MR imaging: A potential reproducible tool for assessing tumour response to treatment with the antiangiogenic compound BIBF 1120, a potent triple angiokinase inhibitor. Eur.Radiol. 18(7), 1414-1421 (2008). 3.Burger, R.A. Overview of anti-angiogenic agents in development for ovarian cancer. Gynecologic Oncology 121(1), 230-238 (2011). 4.Kudo, K.,Arao, T.,Tanaka, K., et al. Antitumor activity of BIBF 1120, a triple angiokinase inhibitor, and use of VEGFR2+pTyr+ peripheral blood leukocytes as a pharmacodynamic biomarker in vivo. Clinical Cancer Research 17(6), 1373-1381 (2011). 5.Richeldi, L.,Costabel, U.,Selman, M., et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. New England Journal of Medicine 365(12), 1079-1087 (2011). 6.Ulahannan, S.V. and Brahmer, J.R. Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer. Cancer Investigation 29(4), 325-337 (2011). | |
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥95% |
| 计算分子量 | 539.6 |
| 分子式 | C31H33N5O4 |
| CAS号 | 656247-17-5 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |